The only medicine to treat the underlying cause of CF in this age group with one F508del mutation and one of 14 residual function mutations... Nov 28
The agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic ... Sep 17
-Advertisements-